View clinical trials related to Multiple Sclerosis.
Filter by:An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
The purpose of this study is to characterize the pharmacokinetic (PK) profile, safety, and tolerability of peginterferon beta-1a (BIIB017) delivered by the single-use autoinjector or prefilled syringe (PFS) in healthy volunteers to support the development of the autoinjector.
This is a randomised, double-blind crossover study to study the effect of intravenous treatment with autologous (derived from the individuals themselves) mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS).
To investigate the ability of a cannabis based medicine extract to relieve chronic refractory pain of neurological origin.
Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.
The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).
This is an observational, retrospective, UK & Ireland audit measuring patient adherence to Rebif® injections with the RebiSmartâ„¢ injection device. Data will be collected from Multiple Sclerosis (MS) patients who have been prescribed Rebif® and have been using the RebiSmartâ„¢ device for injection for a minimum of 24 months.
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis